InsidersTradesSigma
Total declarations
Company
▲ Purchases (0 ops.)
▼ Sales (6 ops.)
Insider track record
CFODisclosed buys
0
Disclosed sells
6
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Signal history
No signal scores available.
Explore the detailed record of transactions filed by Tsuchimoto Kim R, Chief Financial Officer. Director active across 1 company, notably Monopar Therapeutics. Aggregated, 21 reports have been published. Split: 0 buy · 6 sells. Total volume traded: €390k. Activity tracked since 14 July 2025. The latest transaction was disclosed on 26 August 2026 (Cession). Regulator: SEC (Form 4). All data is free.
Companies and markets linked to Tsuchimoto Kim R
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
Declarations21 total
485 shares@ US$108.83Common StockSEC:0001437749-26-029116:0
615 shares@ US$109.56Common StockSEC:0001437749-26-029116:1
700 shares@ US$110.65Common StockSEC:0001437749-26-029116:2
1,098 shares@ US$111.84Common StockSEC:0001437749-26-029116:3
602 shares@ US$112.93Common StockSEC:0001437749-26-029116:4
590 shares@ US$113.84Common StockSEC:0001437749-26-029116:5
8,904 shares@ US$0.005100.0% of flowCommon StockSEC:0001437749-25-022863:0
9,957 sharesCommon StockSEC:0001437749-24-022024:0
9,956 sharesCommon StockSEC:0001437749-24-010722:0
9,957 sharesCommon StockSEC:0001437749-24-000480:0
9,956 sharesCommon StockSEC:0001437749-23-027587:0
14,846 sharesCommon StockSEC:0001437749-23-019258:0
5,067 sharesCommon StockSEC:0001437749-23-009331:0
5,067 sharesCommon StockSEC:0001437749-23-000166:0
5,066 sharesCommon StockSEC:0001654954-22-013282:0
8,913 sharesCommon StockSEC:0001654954-22-009136:0
1,221 sharesCommon StockSEC:0001654954-22-004489:0
1,231 sharesCommon StockSEC:0001654954-22-000128:0
1,221 sharesCommon StockSEC:0001654954-22-000127:0
1,221 sharesCommon StockSEC:0001654954-21-010719:0
2,442 sharesCommon StockSEC:0001654954-21-007597:0
21 of 21 declarations
About Tsuchimoto Kim R
Tsuchimoto Kim R is Director Financier and a director at Monopar Therapeutics (XNAS). There are 15 filings in total, and the sampled recent filings cover the period from 2021-07-02 to 2025-07-16. In this recent sample, the buy and sell amounts are EUR 0 and EUR 0, and the most common transaction type is option exercise.
